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CFTR gene expression is cell-specifically regulated via the influence 
of MAP kinase cascades on the 3' UTR part of the transcripts 
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Legros 1 
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Expression of the CFFR gene is regulated by cyt okines (TNFo: and IL 1[~) in a cell 
specific manner: TNFo: decreases CFTR mRNA in human colon cell lines (HT 29) 
but not ha pulmonary cell lines (Calu 3), IL  1[~ increases it only in Calu 3 cells. To 
precise the mechanisms responsible for the stability of CFFR mRNA, we have 
investigated the posttranscriptional regulation by these cytokines ha HT29 and 
Calu 3 cell in the context of CFTR mRNA 3'untr anslated sequence (3'UTR). 
The stability of CFFR mRNA was analyzed by Northern blot after in vitro 
incubation of cytosolic proteins extracted from control or cytokine treated HT29 
and Calu 3 cells with total RNAs from HeLa cells transfected with either CFTR 
cDNA or CFFR cDNA prolonged with the gene 3'UTR. 
CFTR mRNA was degraded only by extracts of TNFc~ treated HT29 cells and not 
by cytosolic proteins from untreated or IL  1[~ treated HT29 cells, but extracts from 
untreated or TNF c~ treated Calu 3 cells enhanced CFTR mRNA degradation, and 
IL 1[~ pre treatment hahibited this effect. The 3'UTR part of CFFR mRNA was 
found to be required for this posttranscriptional regulation, with poly U segments 
being implicated in CFFR mRNA destabilization and poly C segments ha its 
protection. The proteins which reacted with the U and C repeats of CFFR mRNA 
3'UTR were mainly controlled by stimulation of the p42/p44 and p38 MAP kinase 
cascades with interaction between these pathways. I-~aowing that 3 'UTRs and MAP 
kinase cascades control the expression of many ilfflammatory proteins, we suggest 
that CFTR belongs to the family of these proteins. 
Regulation of CFTRexpression through the interplay of three 
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CFTR expression is tightly regulated both temporally and spatially. However, 
despite extensive studies, no clear mechanism responsible for this control has yet 
been reported. Our current model for regulation of transcriptional ctivity of the 
human CFTR gene proposes that multiple transcription factors interact with a 
previously reported polymorphic and composite CArG like element. Using both 
electrophoretic mobility shift and cbromatin mmunoprecipitation (CbIP) assays, 
we demonstrated that YY 1 and SRF proteins bind this polymolphic YYI/CArG like 
site. These multifunctional regulatory proteins have the potential to interact with 
various co factors including CBP previously described to be involved in remodeling 
cbromatin. Importantly, using multiple cotransfections of expression vectors for 
each one of factors and their dominant negative forms, we demonstrated a positive 
role for both SRF mad CBP factors and a repressive role for YY1. Given the 
functional relationship between either SRF or YY 1 and the CBP proteins previously 
described for a diverse number of promoters, we wondered it" these proteins bind 
each other in vitro and in vivo. In this regard, we recently started coimmuno 
precipitation, GST pulldown and reChIP experiments. 
Taken together, these preliminary data present evidence for a novel regulatory 
complex on the minimal CFTR promoter. This complex involves an interplay and 
functional antagonism between YY1 mad SRF/CBP in the basal CFTR 
transcriptional ctivation. 
A better knowledge of the regulatory elements that control CFTR expression will 
enlighten the understanding of the transcriptional regulation of this gene and 
subsequently improve design of more effective therapies. 
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Human CFTR promoter: a new target for the Upskeam Stimulatory 
Factor (USF) 
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There are cmlently few data that flarow light on the mechanisms of basal tissue 
specific or temporal regulation of the CFI'R gene. Over the past few years, we 
addressed this important and poorly studied field tbr ough the functional analysis of 
some identified sequence variations in the minimal CFTR promoter. The aim of this 
study was to investigate the functional effect of a rare allele (94G>T), which has 
previously been reported only once ha a CF patient with severe cbr onic lung disease. 
Transient ransfection assays with constructs containing the polymorphic CFTR 
minimal promoter, in various cell lines, showed that this nucleotide change induces 
a significant decrease in the basal transcriptional ctivity. Using EMSA and ChIP 
analyses, we demonstrated that USF binds this poly morphic region both in vitro and 
in vivo. Interestingly, USF functionality may be regulated either by an interplay 
between its various isoforms or by interactions dependent on the additional 
cofactors. Furthermore, the original concept of these USF isoforms as ubiquitous 
transcriptional regulators is changing. Indeed, roles of USF ha tissue specific 
promoters regulation, such as surfactant A ha the lung, are increasingly being 
defined. To determine the USF function on the CFTR transcriptional activity, 
cotransfection experiments of various USF expression vectors with their respective 
dominant negative forms and siRNA assays are ha progress. 
Herein, we present the first evidence for a regulatory mutation responsible for CE 
Characterization f various USF isoforms and associated cofactors will ultimately 
yields a rich source insight into USF function in both disease and CFTR 
transcriptional regulation. 
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